The short version of Reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-29. Anything still debated is marked as such rather than presented as settled.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Resveratrol and related polyphenols (usually as "grape seed extract") are often included. Yohimbine has also been used as an ingredient (often as Pausinystalia johimbe extract), as a supposed testosterone booster and fat-loss agent, but it has been associated with dangerous side effects, and is also a prescription medicine in many countries. Phenylpiracetam is also sometimes used as an ingredient for its nootropic and stimulant effects. Capsaicin is sometimes used as an ingredient in gelcap pre-workout formulations, both as a supoosed weight loss aid and for improvement of endurance. Plant extracts, such as Ginkgo biloba, Panax ginseng, Rhodiola rosea and Huperzine A (from Huperzia serrata), are sometimes included for their supposed ability to improve endurance and mental clarity, despite limited evidence for efficacy. Ecdysteroids, such as ecdysterone and turkesterone, and other plant derived steroid like compounds such as 5α-Hydroxylaxogenin are sometimes used as ingredients, despite inconclusive results as to their supposed anabolic effects. Prohormones such as DHEA, CDMA, 1-androstenediol and 7α-methyl-19-norandrostenedione were widely used in pre-workout formulations prior to 2014 when they were formally banned. These compounds are not anabolic agents in their own right, but are metabolised into anabolic steroids of a type which at the time were not restricted.
The BSE SENSEX (also known as the S&P Bombay Stock Exchange Sensitive Index or simply SENSEX) is an Indian free-float market-weighted stock market index of 30 well-established and financially sound companies listed on the Bombay Stock Exchange. The 30 constituent companies which are some of the largest and most actively traded stocks, are representative of various industrial sectors of the Indian economy. Published since 1 January 1986, the S&P BSE SENSEX is regarded as the pulse of the domestic stock markets in India. The base value of the SENSEX was taken as 100 on 1 April 1979 and its base year as 1978–79. On 25 July 2001, BSE launched DOLLEX-, a dollar-linked version of the SENSEX.
Kampo or Kanpō medicine (漢方医学, Kanpō igaku), often known simply as Kanpō (漢方; Japanese medicine) literally means "method from the Han period of Chinese history, but took on specific Japanese characteristics during the Edo period of Japanese history after 1600. One authority writes that Kampo medicine is not the same as modern traditional Chinese medicine (TCM). Japanese Kampo favors diagnostic methods that directly relate the symptoms to the therapy, rather than speculative concepts of traditional philosophy, such as Yin and Yang and the theory of the five elements. Under modern Japanese medical law, it is possible for doctors to perform acupuncture and massage, but because there is a separate law regarding acupuncture and massage, these treatments are mainly performed by massage therapists, acupuncturists, and moxibustion practitioners.
=== Viral-mediated delivery === The gene silencing effects of transfected, designed siRNA are generally transient, but this difficulty can be overcome through an RNAi approach. Delivering this siRNA from DNA templates can be done through several recombinant viral vectors based on retrovirus, adeno-associated virus, adenovirus, and lentivirus. As of primary research work in 2006, the latter virus was the most efficient for stable delivery of siRNA to target cells, as it could be used to transduce nondividing cells, as well as to directly target the nucleus. These specific viral vectors have been synthesized to effectively facilitate siRNA that is not viable for transfection into cells. In some cases synthetic viral vectors can integrate siRNA into the cell genome, which allows for stable expression of siRNA and long-term gene knockdown. This technique is advantageous because it is an in vivo method, and can be effective for difficult to transfect cells. However, problems arise because it can trigger antiviral responses in some cell types, leading to mutagenic and immunogenic effects. This method has been shown to have potential for use in gene silencing of the central nervous system genes, e.g., in the treatment of Huntington's disease.
Sources: en.wikipedia.org
==== APCI MS ==== The source for APCI is similar to ESI except that ions are formed by the interaction of the heated analyte solvent with a corona discharge needle set at a high electrical potential. Primary ions are formed immediately surrounding the needle, and these interact with the solvent to form secondary ions that ultimately ionize the sample. APCI is particularly useful for the analysis of nonpolar lipids such as triacylglycerols, sterols, and fatty acid esters.
== Candidacy relating to elections of the German Federal president == At the 2010 election for the German Federal President, Kermani served as a member of the 14th Federal Assembly at the recommendation of the Green Party of Hessen. And in 2017, Kermani was mentioned as a potential candidate for German Federal President in that year's federal presidential election. According to a report in Der Spiegel, then-SPD chairman Sigmar Gabriel, in cooperation with other parties, had intended to nominate Kermani to run for Federal President. However, the plan failed due to resistance from the Greens. In particular, Kermani was rejected by the Realos wing of the Green Party, because the Realos were aiming to form a Black-Green coalition (i.e. a coalition with the Christian Democrats) subsequent to the general federal elections and thus did not want to be seen as endorsing a Red-Red-Green (i.e. Social Democratic, Left Party and Green Party) coalition.
=== Industry growth === The global blood testing market was valued at approximately USD 96.62 billion in 2024 and is projected to reach USD 160.50 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.83%. The DTC segment represents a rapidly growing portion of this market, fueled by increasing consumer health awareness and technological innovations in sample collection and analysis. North America dominates the market with the largest revenue share (approximately 44.83% in 2024), driven by well-established healthcare infrastructure, favorable regulatory environments in many states, and high consumer acceptance of self-directed healthcare services.
"My mind was, that a dogma was an idea for which there was no reasonable evidence. You see?!" And Crick gave a roar of delight. "I just didn't know what dogma meant. And I could just as well have called it the 'Central Hypothesis,' or — you know. Which is what I meant to say. Dogma was just a catch phrase."
Additionally, the research, in conjunction with studies that show tyrannosaurs were more agile than other large-bodied theropods, indicates they were quite well-adapted to a long-distance stalking approach followed by a quick burst of speed to go for the kill. Analogies can be noted between tyrannosaurids and modern wolves as a result, supported by evidence that at least some tyrannosaurids were hunting in group settings. A study published in 2021 by Pasha van Bijlert et al., calculated the preferred walking speed of Tyrannosaurus, reporting a speed of 1.28 meters per second (4.6 km/h; 2.9 mph). While walking, animals reduce their energy expenditure by choosing certain step rhythms at which their body parts resonate. The same would have been true for dinosaurs, but previous studies did not fully account for the impact the tail had on their walking speeds. According to the authors, when a dinosaur walked, its tail would slightly sway up and down with each step as a result of the interspinous ligaments suspending the tail. Like rubber bands, these ligaments stored energy when they are stretched due to the swaying of the tail. Using a 3-D model of Tyrannosaurus specimen Trix, muscles and ligaments were reconstructed to simulate the tail movements. This results in a rhythmic, energy-efficient walking speed for Tyrannosaurus similar to that seen in living animals such as humans, ostriches and giraffes.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.